Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
Time-related urinary excretion and faecal excretion of 5-ASA and acetyl-5-ASA were measured in eight healthy volunteers after a single oral dose of the azo compounds sulphasalazine and olsalazine, the slow release compounds Pentasa, Asacol and Salofalk, and plain 5-ASA. After ingestion of both azo compounds and slow-release compounds, urinary excretion of 5-ASA was markedly delayed and reduced, and faecal excretion was enhanced. At all points of time, there was a significant, but not very marked difference in urinary excretion of 5-ASA after ingestion of the azo compounds and the slow-release compounds, in favour of the azo compounds. A significantly larger proportion of the ingested 5-ASA, moreover, was excreted in faeces after the intake of azo compounds as compared with slow-release compounds.
Rijk
M C
MC
Department of Gastroenterology, University Hospital Nijmegen, The Netherlands.
van Schaik
A
A
van Tongeren
J H
JH
D000328:Adult; D000636:Aminosalicylic Acids / Q000493:pharmacokinetics*; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine; D012460:Sulfasalazine / Q000493:pharmacokinetics
D000636:Aminosalicylic Acids; D003692:Delayed-Action Preparations; D012460:Sulfasalazine; D019804:Mesalamine; C028836:N-acetyl-5-aminosalicylic acid; C032587:olsalazine